688428 诺诚健华
已收盘 05-08 15:00:01
资讯
新帖
简况
诺诚健华（688428）披露证券变动月报表，5月8日股价下跌2.48%
证券之星 · 05-08 18:08
诺诚健华（688428）披露证券变动月报表，5月8日股价下跌2.48%
诺诚健华TYK2抑制剂ICP-488在华获批开展干燥综合征II期临床试验
美股速递 · 05-08 08:31
诺诚健华TYK2抑制剂ICP-488在华获批开展干燥综合征II期临床试验
诺诚健华（688428）披露持股5%以上股东权益变动触及1%刻度公告，5月6日股价下跌1.28%
证券之星 · 05-06 17:32
诺诚健华（688428）披露持股5%以上股东权益变动触及1%刻度公告，5月6日股价下跌1.28%
每周股票复盘：诺诚健华（688428）股东权益变动触及1%刻度
证券之星 · 05-02
每周股票复盘：诺诚健华（688428）股东权益变动触及1%刻度
港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告
智通财经 · 04-28
港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告
诺诚健华（688428）披露2026年股东周年大会通知，4月27日股价下跌1.97%
证券之星 · 04-27
诺诚健华（688428）披露2026年股东周年大会通知，4月27日股价下跌1.97%
每周股票复盘：诺诚健华（688428）Q1营收5.29亿元同比增长38.65%
证券之星 · 04-26
每周股票复盘：诺诚健华（688428）Q1营收5.29亿元同比增长38.65%
诺诚健华(09969)授出1538.92万份受限制股份单位
智通财经 · 04-24
诺诚健华(09969)授出1538.92万份受限制股份单位
诺诚健华：公司预计2026年药品销售收入将继续稳健增长
证券日报 · 04-24
诺诚健华：公司预计2026年药品销售收入将继续稳健增长
智通港股早知道 | 碳达峰碳中和综合评价考核办法印发 诺诚健华(09969)一季度归母净利润同比增加488.93%
智通财经 · 04-24
智通港股早知道 | 碳达峰碳中和综合评价考核办法印发 诺诚健华(09969)一季度归母净利润同比增加488.93%
复星医药筹划出售资产；诺诚健华一季度净利润同比增长488.93%｜医药早参
每日经济新闻 · 04-24
复星医药筹划出售资产；诺诚健华一季度净利润同比增长488.93%｜医药早参
图解诺诚健华一季报：第一季度单季净利润同比增长488.93%
证券之星 · 04-24
图解诺诚健华一季报：第一季度单季净利润同比增长488.93%
诺诚健华：2026年一季度盈利1亿元
南方财经网 · 04-23
诺诚健华：2026年一季度盈利1亿元
诺诚健华：一季度净利润1.06亿元 同比增长488.93%
每日经济新闻 · 04-23
诺诚健华：一季度净利润1.06亿元 同比增长488.93%
每周股票复盘：诺诚健华（688428）将召开2026年Q1业绩说明会
证券之星 · 04-19
每周股票复盘：诺诚健华（688428）将召开2026年Q1业绩说明会
诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%
证券之星 · 04-15
诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%
诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户
证券日报 · 04-07
诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户
每周股票复盘：诺诚健华（688428）证券数量无变动
证券之星 · 04-05
每周股票复盘：诺诚健华（688428）证券数量无变动
诺诚健华（688428）披露证券变动月报表，4月3日股价下跌1.9%
证券之星 · 04-03
诺诚健华（688428）披露证券变动月报表，4月3日股价下跌1.9%
3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股
证券之星 · 03-30
3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":26.35,"timestamp":1778223601000,"preClose":27.02,"halted":0,"volume":11665689,"delay":0,"changeRate":-0.0248,"floatShares":268000000,"shares":1764999999,"eps":0.4139,"marketStatus":"已收盘","change":-0.67,"latestTime":"05-08 15:00:01","open":27.2,"high":27.47,"low":26.25,"amount":311000000,"amplitude":0.0452,"askPrice":26.35,"askSize":174,"bidPrice":26.33,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.4139,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":27.02,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":29.72,"lowLimit":24.32,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":6.33,"roa":"--","peRate":63.66272,"roe":"1.4%","epsLYR":0.38,"committee":0.281759,"marketValue":46498000000,"turnoverRate":0.0435,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-11。","afterMarket":{"amount":0,"volume":0,"close":26.35,"buyVolume":0,"sellVolume":0,"time":1778225637558,"indexStatus":"已收盘 05-08 15:30:00","preClose":27.02},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.51,"timestamp":1778227683009,"preClose":13.93,"halted":0,"volume":5875393,"delay":0,"premium":"-55.50"},"floatMarketCap":7071000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2633342404","title":"诺诚健华（688428）披露证券变动月报表，5月8日股价下跌2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633342404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633342404?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:08","pubTimestamp":1778234927,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，诺诚健华报收于26.35元，较前一交易日下跌2.48%，最新总市值为464.98亿元。该股当日开盘27.2元，最高27.47元，最低26.25元，成交额达3.11亿元，换手率为4.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","161027","688428","09969","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124802514","title":"诺诚健华TYK2抑制剂ICP-488在华获批开展干燥综合征II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1124802514","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124802514?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:31","pubTimestamp":1778200273,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，其创新药物TYK2抑制剂ICP-488针对干燥综合征的II期临床试验申请已获得中国监管部门批准。该进展标志着公司在自身免疫疾病治疗领域取得重要突破。ICP-488作为高选择性TYK2抑制剂，通过精准调控JAK-STAT信号通路，有望为干燥综合征患者提供新的治疗选择。此次获批的II期临床试验将系统评估该药物在中国患者群体中的安全性和有效性，为后续临床开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633183907","title":"诺诚健华（688428）披露持股5%以上股东权益变动触及1%刻度公告，5月6日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633183907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633183907?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:32","pubTimestamp":1778059940,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，诺诚健华报收于26.31元，较前一交易日下跌1.28%，最新总市值为464.28亿元。该股当日开盘26.5元，最高26.68元，最低26.2元，成交额达2.79亿元，换手率为3.94%。公司近日披露《关于持股5%以上股东权益变动触及1%刻度的提示性公告》。本次权益变动方式为港股减持，不触及要约收购，不会导致公司控制权变化，对公司治理结构及持续经营无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600027518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623572","title":"每周股票复盘：诺诚健华（688428）股东权益变动触及1%刻度","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623572","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623572?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:01","pubTimestamp":1777672902,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，诺诚健华报收于26.65元，较上周的28.47元下跌6.39%。本周，诺诚健华4月27日盘中最高价报28.3元。本周关注点公司公告汇总：持股5%以上股东权益变动触及1%刻度，持股比例由8.21%减少至7.98%公司公告汇总诺诚健华医药有限公司持股5%以上股东Sunny View Holdings Limited及其一致行动人Wellesley Hill Holdings Limited、Grandview Irrevocable Trust、Renbin Zhao（赵仁滨）、施一公合计持有公司股份数量由14,481.7893万股减少至14,081.7893万股，持股比例由8.21%减少至7.98%，权益变动触及1%刻度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","BK1161","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347483","title":"港股异动 | 诺诚健华(09969)涨近3% Mesutoclax治疗髓系恶性肿瘤研究入选ASCO 2026年会口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347483","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347483?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:51","pubTimestamp":1777341060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华(09969)涨近3%，截至发稿，涨2.67%，报14.24港元，成交额2919.93万港元。消息面上，4月27日，据诺诚健华官微消息，公司宣布，自研新型BCL2抑制剂Mesutoclax(ICP-248)和新型BTK抑制剂奥布替尼的多项研究成果入选2026年美国临床肿瘤学会(ASCO)年会。其中，Mesutoclax治疗髓系恶性肿瘤的研究入选口头报告，Mesutoclax治疗B细胞恶性肿瘤的研究入选海报展示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","09969","BK0239","688428","BK1574","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630236060","title":"诺诚健华（688428）披露2026年股东周年大会通知，4月27日股价下跌1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630236060","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630236060?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:36","pubTimestamp":1777286164,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，诺诚健华报收于27.91元，较前一交易日下跌1.97%，最新总市值为492.51亿元。该股当日开盘28.0元，最高28.3元，最低27.17元，成交额达3.52亿元，换手率为4.75%。近日，诺诚健华医药有限公司发布《关于召开2026年股东周年大会的通知》。公告显示，公司将于2026年6月16日召开2026年股东周年大会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK1574","BK0239","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630805801","title":"每周股票复盘：诺诚健华（688428）Q1营收5.29亿元同比增长38.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630805801","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630805801?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:02","pubTimestamp":1777140138,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，诺诚健华报收于28.47元，较上周的30.8元下跌7.56%。本周，诺诚健华4月20日盘中最高价报31.35元。本周关注点来自业绩披露要点：诺诚健华2026年一季报显示，一季度公司主营收入5.29亿元，同比上升38.65%。当前公司经营正常，商业化销售持续放量，研发管线推进顺利，2026年第一季度药品销售收入4.50亿元，同比增长44.54%，总营业收入5.29亿元，同比增长38.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600000624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629244844","title":"诺诚健华(09969)授出1538.92万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2629244844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629244844?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:18","pubTimestamp":1777036724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2026年4月24日，公司根据2023年股权激励计划向3名承授人授出1538.92万份受限制股份单位，相当于公司于本公告日期已发行股份总数(不包括库存股份)约0.87%。向相关执行董事授出受限制股份单位受限于及须待股东于应届股东周年大会批准后，方可作实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK0239","BK1161","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629084938","title":"诺诚健华：公司预计2026年药品销售收入将继续稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2629084938","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629084938?lang=zh_cn&edition=full","pubTime":"2026-04-24 19:47","pubTimestamp":1777031220,"startTime":"0","endTime":"0","summary":"证券日报网4月24日讯，诺诚健华在接受调研者提问时表示，2026年第一季度，公司药品销售增长主要来自于核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增贡献，在三款产品组合驱动下，公司预计2026年药品销售收入将会继续稳健增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243718356725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1161","688428","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629486467","title":"智通港股早知道 | 碳达峰碳中和综合评价考核办法印发 诺诚健华(09969)一季度归母净利润同比增加488.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629486467","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629486467?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:21","pubTimestamp":1776986463,"startTime":"0","endTime":"0","summary":"中共中央办公厅、国务院办公厅印发《碳达峰碳中和综合评价考核办法》中共中央办公厅、国务院办公厅印发《碳达峰碳中和综合评价考核办法》。权益变动后，宁波联创持有公司股份比例由6.23%降至4.96%，不再具有大股东身份。诺诚健华发布第一季度业绩，归母净利润1.06亿元 同比增加488.93%诺诚健华发布2026年第一季度报告，该集团取得营业收入5.29亿元，同比增加38.65%;归属于上市公司股东的净利润1.06亿元，同比增加488.93%;基本每股收益0.06元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","159790","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629486439","title":"复星医药筹划出售资产；诺诚健华一季度净利润同比增长488.93%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629486439","media":"每日经济新闻","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629486439?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985208,"startTime":"0","endTime":"0","summary":"｜2026年4月24日星期五｜NO.1九洲药业一季度净利润1.72亿元同比减少31.22%4月23日，九洲药业公告，公司2026年第一季度实现营业收入12.01亿元，同比下降19.43%；利润总额2.20亿元，同比下降29.20%；归属于上市公司股东的净利润1.72亿元，同比减少31.22%，主要系销售业务减少所致；经营活动产生的现金流量净额1.36亿元，同比下降52.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716839096.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716839096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","09969","09939","600196","159938","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852312","title":"图解诺诚健华一季报：第一季度单季净利润同比增长488.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852312","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852312?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:22","pubTimestamp":1776968577,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华2026年一季报显示，一季度公司主营收入5.29亿元，同比上升38.65%；归母净利润1.06亿元，同比上升488.93%；扣非净利润9592.96万元，同比上升5927.02%；负债率29.09%，投资收益546.98万元，财务费用-2196.33万元，毛利率88.14%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400006049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629780833","title":"诺诚健华：2026年一季度盈利1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629780833","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629780833?lang=zh_cn&edition=full","pubTime":"2026-04-23 18:51","pubTimestamp":1776941460,"startTime":"0","endTime":"0","summary":"南方财经4月23日电，生物医药企业诺诚健华（09969.HK/688428.SH）披露2026年一季报，2026年第一季度药品收入同比增长44.5%至4.5亿元，由于药品收入的持续上涨以及全球商务拓展（BD），公司2026年第一季度总收入同比增长38.7%至5.3亿元，同期净利润1.0亿元。在此之前，公司于2025年首次实现年度盈利，归母净利润6.42亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716270246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK0239","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629942887","title":"诺诚健华：一季度净利润1.06亿元 同比增长488.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629942887","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629942887?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:55","pubTimestamp":1776938113,"startTime":"0","endTime":"0","summary":"诺诚健华(688428)4月23日披露一季报，公司2026年一季度实现营业收入5.29亿元，同比增长38.65%；归母净利润1.06亿元，同比增长488.93%，主要系公司核心产品奥布替尼持续放量、坦昔妥单抗和佐来曲替尼新增贡献以及公司与Zenas的授权许可协议完成后续里程碑交付。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604233716186676.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716186676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628775930","title":"每周股票复盘：诺诚健华（688428）将召开2026年Q1业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2628775930","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628775930?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:29","pubTimestamp":1776536946,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，诺诚健华报收于30.8元，较上周的28.89元上涨6.61%。本周，诺诚健华4月16日盘中最高价报31.91元。4月13日盘中最低价报28.15元。诺诚健华当前最新总市值543.51亿元，在化学制药板块市值排名9/150，在两市A股市值排名372/5198。参会人员包括董事会主席兼行政总裁Jisong Cui博士、独立非执行董事胡兰女士、首席财务官傅欣先生及信息披露境内代表袁蓓女士。说明会后可通过该平台查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688428","BK1161","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627238931","title":"诺诚健华（688428）披露2026年第一季度业绩说明会公告，4月15日股价上涨7.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238931","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627238931?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:05","pubTimestamp":1776261917,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，诺诚健华报收于31.17元，较前一交易日上涨7.93%，最新总市值为550.04亿元。该股当日开盘29.49元，最高31.82元，最低28.88元，成交额达6.28亿元，换手率为7.74%。公告显示，公司将于2026年4月24日上午11:00-12:00通过上证路演中心网络互动方式召开2026年第一季度业绩说明会，介绍公司当季经营成果及财务状况。投资者可于4月17日至4月23日16:00前通过上证路演中心网站或公司邮箱IR@innocarepharma.com提交问题。说明会后可通过该平台查看会议情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500042904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK1574","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625934106","title":"诺诚健华：截至2026年3月20日公司A股股东户数约为1.93万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2625934106","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625934106?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:14","pubTimestamp":1775556840,"startTime":"0","endTime":"0","summary":"证券日报网讯4月7日，诺诚健华在互动平台回答投资者提问时表示，截至2026年3月20日公司A股股东户数约为1.93万户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696569528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","399300","159982","09969","688428","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625151786","title":"每周股票复盘：诺诚健华（688428）证券数量无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2625151786","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625151786?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:17","pubTimestamp":1775323029,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，诺诚健华报收于29.38元，较上周的25.3元上涨16.13%。本周，诺诚健华4月2日盘中最高价报30.29元。诺诚健华当前最新总市值518.45亿元，在化学制药板块市值排名9/150，在两市A股市值排名357/5193。本周关注点公司公告汇总：诺诚健华截至2026年3月31日证券数量无变动，股份总数与上月底结存一致。此外，2023年及2024年人民币股股权激励计划项下部分限制性股票失效，但本月未因协议安排导致股份增减。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688428","BK0239","09969","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624366824","title":"诺诚健华（688428）披露证券变动月报表，4月3日股价下跌1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624366824","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624366824?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:05","pubTimestamp":1775225120,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，诺诚健华报收于29.38元，较前一交易日下跌1.9%，最新总市值为518.45亿元。该股当日开盘29.51元，最高30.16元，最低28.6元，成交额达6.59亿元，换手率为8.32%。近日，诺诚健华发布港股公告《证券变动月报表》。公告显示，截至2026年3月31日，公司法定注册资本无变动，已发行股份总数与上月底结存一致，无增减。此外，2023年及2024年人民币股股权激励计划项下部分限制性股票失效，但本月未因协议安排导致股份增减。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","09969","688428","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623281397","title":"3月30日诺诚健华涨7.08%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623281397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623281397?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:26","pubTimestamp":1774859203,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日诺诚健华涨7.08%创60日新高，收盘报27.09元，换手率9.07%，成交量24.33万手，成交额6.52亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元，最新净值3.126，较上一交易日上涨6.93%，近一年上涨22.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","BK1161","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778311930518,"stockEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.1349},{"period":"3month","weight":0.097},{"period":"6month","weight":0.1044},{"period":"1year","weight":0.2885},{"period":"ytd","weight":0.2841}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19000人(较上一季度减少5.00%)","perCapita":"14124股","listingDate":"2022-09-21","address":"Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}